Atos SE:企業のM&A・事業提携・投資動向

◆英語タイトル:Atos SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
◆商品コード:DATA904C2331
◆発行会社(調査会社):MarketLine
◆発行日:2018年7月
◆ページ数:114
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:技術・通信
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD350 ⇒換算¥51,800見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD700 ⇒換算¥103,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD1,050 ⇒換算¥155,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
MarketLine社の概要はこちらでご確認いただけます。



【レポートの概要】

Atos SE – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Summary

Marketline’s Atos SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Atos SE since January2007.

Synopsis

Marketline’s Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Key Highlights

This report includes Atos SE’s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.

The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Atos SE. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.

Scope

- Provides intelligence on Atos SE’s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Atos SE and its subsidiaries since 2007.
- Information about key financial and legal advisors for Atos SE’s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.

Reasons to buy

- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Atos SE’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.

【レポートの目次】

Table of Contents
COMPANY OVERVIEW AND KEY FACTS 2
TABLE OF CONTENTS 5
LIST OF TABLES 7
LIST OF FIGURES 7
TARGETS AND PARTNERS 8
MERGERS & ACQUISITIONS 9
Mergers and Acquisitions – Overview 9
Mergers and Acquisitions – Deal reports 10
PARTNERSHIP 60
Partnership – Overview 60
Partnership – Deal reports 61
CAPITAL RAISING 71
Capital Raising – Overview 71
Capital Raising – Deal reports 72
DIVESTMENTS 76
Divestments – Overview 76
Divestments – Deal reports 77
PRIVATE EQUITY & OWNERSHIP 88
Private Equity and Ownership – Deal reports 88
APPENDIX 104
Contact Us 104
About MarketLine Financial Deals Database 104
Deal Definition and Methodology 106
About MarketLine 113

List of Tables
Table 1: Atos SE M&A volume and value trend (2014-YTD2018)
Table 2: Atos SE M&A activity by geography (2014-YTD2018)
Table 3: Atos SE partnership volume and value trend (2014-YTD2018)
Table 4: Atos SE partnership trend by key deal type (2014-YTD2018)
Table 5: Atos SE capital raising volume and value trend (2014-YTD2018)
Table 6: Atos SE capital raising by deal type (2014-YTD2018)
Table 7: Atos SE divestments volume and value trend (2014-YTD2018)
Table 8: Atos SE divestments activity by geography (2014-YTD2018)

List of Figures
Figure 1: Atos SE M&A volume and value trend (2014-YTD2018)
Figure 2: Atos SE M&A activity by geography (2014-YTD2018)
Figure 3: Atos SE partnership volume and value trend (2014-YTD2018)
Figure 4: Atos SE partnership trend by key deal type (2014-YTD2018)
Figure 5: Atos SE capital raising volume and value trend (2014-YTD2018)
Figure 6: Atos SE capital raising by deal type (2014-YTD2018)
Figure 7: Atos SE divestments volume and value trend (2014-YTD2018)
Figure 8: Atos SE divestments by geography (2014-YTD2018)

★海外企業調査レポート[Atos SE:企業のM&A・事業提携・投資動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Animalcare Group Plc (ANCR):企業の財務・戦略的SWOT分析
    Summary Animalcare Group Plc (Animalcare) is a animal healthcare service provider that develops and supplies veterinary medicines and services. The company offers products such as licensed veterinary medicines, companion animal identification and animal welfare products. It offers its product to dog …
  • Obagi Medical Products Inc-製薬・医療分野:企業M&A・提携分析
    Summary Obagi Medical Products Inc (Obagi), a subsidiary of Valeant Pharmaceuticals International Inc is a drug company that manufactures, sells, and markets skin care systems. The company provides products that include targeted solutions, tretinoin products, transformation systems, skin recovery, i …
  • Compagnie Plastic Omnium SA (POM):企業の財務・戦略的SWOT分析
    Compagnie Plastic Omnium SA (POM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Biolase, Inc. (BIOL)-医療機器分野:企業M&A・提携分析
    Summary Biolase, Inc. (Biolase) is medical device company which develops, manufactures, markets and sells dental lasers and related products. It also distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. The company offers two categories of laser s …
  • Eastern Company SAE:企業の戦略・SWOT・財務分析
    Eastern Company SAE - Strategy, SWOT and Corporate Finance Report Summary Eastern Company SAE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pulmatrix Inc (PULM):企業の財務・戦略的SWOT分析
    Summary Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that discovers and develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline products using its proprieta …
  • U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報
    Summary U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal f …
  • Nexen Energy ULC:石油・ガス:M&Aディール及び事業提携情報
    Summary Nexen Energy ULC (Nexen Energy), formerly Nexen Inc., a subsidiary of CNOOC Limited, is an upstream oil and gas company that discovers and develops energy resources. It is involved in the production of conventional oil and gas, oil sands, and shale gas. The company’s activities include explo …
  • Core-Mark Holding Company, Inc.:企業の戦略・SWOT・財務情報
    Core-Mark Holding Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Core-Mark Holding Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Nichias Corp (5393):企業の財務・戦略的SWOT分析
    Nichias Corp (5393) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野:企業M&A・提携分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive canna …
  • Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析
    Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • 3i Group Plc:企業のM&A・事業提携・投資動向
    3i Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3i Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • LongReach Group Limited:企業の戦略・SWOT・財務情報
    LongReach Group Limited - Strategy, SWOT and Corporate Finance Report Summary LongReach Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Saudi Electricity Co:企業の発電所・SWOT分析2018
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Debiopharm International SA-製薬・医療分野:企業M&A・提携分析
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Sherwin-Williams Co (SHW):企業の財務・戦略的SWOT分析
    Sherwin-Williams Co (SHW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Panmure Gordon & Co Limited:企業の戦略的SWOT分析
    Panmure Gordon & Co Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • The Leukemia & Lymphoma Society Inc-製薬・医療分野:企業M&A・提携分析
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a health organization that offers funding research, finding cures and access to treatments for blood cancer patients. The organization’s services include patient support, health education, policy advocacy, funds raising and medical research fundin …
  • Housing Development Finance Corporation Ltd:企業のM&A・事業提携・投資動向
    Housing Development Finance Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Housing Development Finance Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆